Eli Lilly targets alleged black market sales of its experimental GLP-1 drug

Eli Lilly is suing six entitles that it alleges are selling black market versions of its experimental weight loss drug retatrutide.  Lilly’s lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss “hack.

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment  WSJ

Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.

The drug remains in Phase 3 clinical trials and has not been approved by any regulator for human use

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide  Reuters

The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.